TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sleep-dependent procedural memory consolidation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Demand for Rescue Analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of Eg and/or Pg receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Exacerbation Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Had Regression or No Progression in Tanner Staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Suppurative Exacerbations Per Patient Per Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Hospitalizations and Urgent/Unscheduled Outpatient Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Feasibility of study recruitment and retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Costs associated with cystoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of HTCs which agree to participate in the pilot phase of the WBDR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participating HTCs who successfully obtain necessary regulatory approval
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients who agree to participate in this pilot phase of the WBDR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of enrolled patients on which data collection and database entry is successful
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Micronuclei formation in binucleated cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen-induced platelet aggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Biochemical cure of hyperparathyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of implant procedure related and lead-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in glucagon-like peptide 1 (GLP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ADHD IV Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone speed of sound values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician compliance with in-hospital drug prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physician compliance with discharge drug prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postprandial changes in interstitial glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial changes in plasma insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial changes in plasma triglyceride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reproducibility of PET tracer for CB1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glannular dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Penile rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urethral diverticulum
Endpoint domain: Adverse events/effects
Primary endpoint: Quantitative Measurement of [18F]-FPIA Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Repeated Use of website measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discrimination of atrial fibrillation from normal heart rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in concentration of circulating MDSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Minutes of moderate-to-vigorous physical activity (MVPA)/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Low Shear Blood Viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change in High Shear Blood Viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Measurement of biomarker prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Measurement of biomarker lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma glucagon responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of post-operative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Keyhole Limpet Hemocyanin (KLH) Responders at Day 28 Post-Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Tetanus Diphtheria Toxoid (Td) Responders at Day 28 Post-Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients achieving full feed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate to severe flare requiring hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: maximum decrease in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3 month clinical-functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The occurrence of Cerebral Edema
Endpoint domain: Adverse events/effects
Primary endpoint: The occurrence of Haemorrhagic Transformation
Endpoint domain: Adverse events/effects
Primary endpoint: The occurrence of relevant Haemorrhagic Transformation
Endpoint domain: Adverse events/effects
Primary endpoint: Alveolar macrophage (AM) phagocytic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phagocytosis percent positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: New White Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of family planning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of clinically significant changes in vital signs: Blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volume of distribution (VT) of [18F]MNI-1216
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with [18F]MNI-1216-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Somatosensory evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Drinking Outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with at least one ADE
Endpoint domain: Adverse events/effects
Primary endpoint: Hypertrophy ratio of FLR volume / total liver volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic deterioration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median Time of Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Dental restorations assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Did Not Require Rescue Administration of Propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static and dynamic postural balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of Stroke Volume Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and Severity of Ocular TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Intraocular Pressure (IOP) for Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Prevalence of Anxiety Episodes (Crohn's Disease)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Anxiety Episodes (Ulcerative Colitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Depressive Episodes (Crohn's Disease)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Depressive Episodes (Ulcerative Colitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of People With Depressive Disorder in People With and Without Crohn's Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Walking time in daily life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of time spent in moderate intense activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of study procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: functional delayed graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: primary nonfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sustained response (HBV DNA level <2000 IU/ml at week 48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Static and dynamic balance using the Mobility lab (APDM-sensors)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four Test Balance Scale (4TBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Developed a New Pressure Ulcer Category 2 or Worse
Endpoint domain: Adverse events/effects
Primary endpoint: Depigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 10-year UKPDS coronary event risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD8 cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Range of absorbed doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment response in temporomandibular joint arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression (TTP2)
Endpoint domain: Mortality/survival
Primary endpoint: Area under the curve to time t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vascular monitoring process total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical entity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognosis of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of PPG for the diagnosis of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of constipation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neonatal Respiratory Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maternal Reflective Functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of CIN2/CIN3+ lesions
Endpoint domain: Mortality/survival
Primary endpoint: Preventing Death
Endpoint domain: Mortality/survival
Primary endpoint: Preventing Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete cure of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in salivary Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximal levels of salivary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: child's heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: child's respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: child's blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC of numerical pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Discontinued the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Engagement in Firearm Safety Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Peak percent reduction in PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: executive function composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety of FURESTEM-RA Inj.
Endpoint domain: Adverse events/effects
Primary endpoint: mean striatal uptake of [123I]B-CIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder versus Non-Responder Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants for Which Angiography is Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Trunk stabilization test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Plasma Glucose Area Under the Concentration-time Curve (AUC0-4h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Reported Outcome Measurement Information System Short Form v1.0
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to complete dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the insulin degludec concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of subjects with a dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects with Detected Extrahepatic Non-target Embolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tolerability of treatment schedules
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of rofecoxib addition to chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of prolonged continuous infusion of gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pre-transplant disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggravation of secondary mitral insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: High-sensitivity C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of symptomatic stroke and systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Serum sodium change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative efficiency of analgesic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apixaban pharmacokinetics (Cmax, C24, AUClast, AUCinf, Tmax, half-life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose proportionality of BAY94-8862 exposure in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Systolic Blood Pressure at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Diastolic Blood Pressure at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Pulse Rate at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Wound Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous lymphocytic infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Reach of cervical cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hepatitis B Virus (HBV) DNA Suppression and HBeAg Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of Gleno-humeral Subluxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Capabilities of the Upper Extremity (CUE) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: QTcB Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of Lymphocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptom Changes - PANSS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ABO-OGS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Confidence Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychotic symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic inclination measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity in blood, plasma urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood-Brain Barrier (BBB) opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Conversion to Psychosis
Endpoint domain: Mortality/survival
Primary endpoint: Post-Appointment IBD related Hospital Admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prescribed dose of Iclusig®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of collection of CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of infusion of gene modified cells
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Battery Test at 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Battery Test at 24 Months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Unsupervised BCI performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of heart failure with midrange and preserved ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in endothelial function evaluated by flow-mediated vasodilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of hemodynamic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative nausea and vomiting 6 hours after caesarian section
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative nausea and vomiting 24 hours after caesarian section
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with normonatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extent of resection of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Derangements of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Adrenomedullin plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reported quit status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FFDM Mammogram Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in length and width of the donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes